Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0QZU.L | BIIB | KRYS | SION | PTCT | VIR | |
|---|---|---|---|---|---|---|
| Market cap | — | 34.80B | 9.48B | 180.15M | 5.13B | 1.72B |
| P/E (TTM) | 52.4 | 41.8 | 40.1 | — | — | — |
| Forward P/E | — | 14.3 | 35.4 | -1.8 | 25.9 | -4.1 |
| Price/book | 6.2 | 1.8 | 7.0 | 0.7 | -30.9 | 1.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +37.54% | +58.66% | +61.55% | −87.92% | −13.34% | +58.85% |
| Today | −0.58% | +1.25% | +1.15% | +2.57% | +3.67% | +1.86% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0QZU.L news ›3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Posted by Defense World Staff on Oct 17th, 2026 NASDAQ:VRTX opened at $499.74 on Friday. The stock’s fifty day moving average is $523.54 and its 200 day moving average is $480.55. Vertex Pharmaceuticals Incorporated has a fifty-two week…
How Vertex Pharmaceuticals Incorporated (VRTX) Affects Rotational Strategy Timing
Stock Traders Daily Key findings for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) - Weak Near and Mid-Term Sentiment Could Challenge Long-Term Positive Outlook - Exceptional 25.9:1 risk-reward short setup targets 7.5% downside vs…
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653
www.marketscreener.com Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 Published on 10/15/2026 at 06:40 am EDT
Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children
Vertex Pharmaceuticals said Friday that new interim data from an open-label extension study evaluating Alyftrek in cystic fibrosis showed that some pediatric patients aged 2 to 5 years recovered... Vertex Pharmaceuticals Says Alyftrek…
Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated announced new interim data from the ALYFTREK® 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children...
DC Circuit Agrees Vertex Pharmaceuticals’ Fertility Support Program Would Violate Anti-Kickback Statute
On September 4, the US Court of Appeals for the DC Circuit ruled that the US Department of Health and Human Services Office of the Inspector General (HHS-OIG) properly found that Vertex Pharmaceuticals’ Fertility Support Program would…
Citi Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
The Globe and Mail Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $585.00. Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Regeneron, and Bristol-Myers…
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Can the pioneer of mRNA vaccines outpace the king of cystic fibrosis treatments? Choosing between Moderna (MRNA -5.00%) and Vertex Pharmaceuticals (VRTX -0.60%) requires weighing high-growth potential against established, profitable market…
Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
Traders Union
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com15
-
fool.com4
-
theglobeandmail.com4
-
gurufocus.com2
-
themarketsdaily.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 36 articles, not a forecast.